A European biotechnology company, developing novel mitochondria-targeted drugs for treatment of neurodegenerative and metabolic diseases. The company's goal is to develop and market a set of innovative pharmaceuticals based on new type of biologically active compounds - mitochondrially targeted ferroptosis inhibitors - in the U.S. and Europe.
There is no investment information
No recent news or press coverage available for Mitotech S.A..